Delivery Order SPE2DB20D3103-SPE2DB25FQ4X5
Award Date 9/27/25
Potential Completion Date 9/29/25
Potential Value $24K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ruxience 500 mg/50 mL vials with a contract value of $2,935.32 and a completion date of August 5, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed-price pricing and represents a pharmaceutical supply transaction under the company's existing Indefinite Delivery Contract relationship with DLA. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ruxience 100 mg/10 mL vials valued at $1,956.80 under a firm fixed-price contract. This delivery order represents a non-set-aside competitive award and is part of a larger indefinite delivery contract (IDC) vehicle designated SPE2DX with the DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed and delivered...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Ruxience 500 mg/50 ml vials. This non-set-aside, competitively awarded contract is valued at $13,615.33 and features firm fixed pricing, with an ultimate completion date of August 7, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Ruxience 500 mg/50 ml vials, with a contract ceiling value of $5,381.40. The contract is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was not set aside and was competitively awarded through open procurement processes, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ruxience 500 mg/50 ml vials, a biosimilar monoclonal antibody used in cancer and autoimmune disease treatment. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $4,892.20 and an ultimate completion date of August 15, 2025. The contract involves no set-aside designation and utilizes AmerisourceBergen's place of performance in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $19,118.40 firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RUXIENCE 500 MG/50 ML VIAL 50ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $13,796.78 order is for the supply of RUXIENCE 500 MG/50 ML VIAL 50ML, a pharmaceutical product, to support military treatment programs and facilities. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ruxience 500 mg/50 mL vials with a ceiling value of $9,784.40 under a firm fixed price contract. This delivery order represents a non-set-aside, competitively awarded procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in cancer treatment and other therapeutic applications,...